India, March 9 -- image credit- freepik
Agilent Technologies Inc. has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.
Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialised antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.